Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Future Oncol
; 13(5s): 7-9, 2017 Feb.
Article
em En
| MEDLINE
| ID: mdl-28116939
ABSTRACT
We present the case of a 70-year-old man diagnosed with multiple myeloma in 2008, who after four therapy lines initiated a fifth-line treatment with pomalidomide (4 mg orally, days 1-21 of a 28-day cycle) and low-dose dexamethasone (40 mg weekly orally). The patient was treated with pomalidomide for almost 2 years achieving a complete remission after 12 cycles. Complete remission was maintained for 9 months. This case illustrates the potential of pomalidomide plus low-dose dexamethasone to overcome multiple myeloma refractoriness inducing a quick and very prolonged remission.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Talidomida
/
Fatores Imunológicos
/
Mieloma Múltiplo
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Itália